NWPF

News ArchivesRead News

Biology professor studies leeches for clues to Parkinson's

Thursday September 24, 2009

Mara Kumagai Fink

St. Olaf College News - When most people think of leeches, they envision blood-sucking creatures that attack during summer swims or are found among similarly slimy creatures in bait shops. But when St. Olaf Assistant Professor of Biology Kevin Crisp looks at leeches, he sees a key to unlocking the mysteries of Parkinson’s disease.

Crisp recently received a $45,000 grant to study how dopamine affects the neurons in leech cells that trigger movement. In simpler terms, he’s researching how a leech decides to move.

Although a simple leech brain may seem far removed from the complex human brain, the basic principles by which both leeches and humans make decisions is very similar. Figuring out how dopamine makes neural circuits turn out the appropriate movement at the appropriate time in a leech could help in human research as well.

Although it is nearly impossible to find out which neurons trigger certain actions in humans who are making a straightforward decision such as what to eat for dinner, leeches have a simpler development that makes it easier to pinpoint which cells do what.

Crisp hopes that the information he’s gathering in the study will someday be transferrable to Parkinson’s patients. Parkinson’s disease occurs because there is a decreased amount of dopamine in the brain. General practice for treating Parkinson’s is to increase the amount of dopamine in a person’s brain. But nobody is sure how the dopamine actually works at the neuron level.

“The doctors who are administering the management are sort of cheating. We’re sort of shooting in the dark here,” Crisp says. “We know you throw dopamine at a system in sufficient quantities and the disease becomes manageable; we just don’t know how or why, so we’re trying to figure that ‘why’ bit out.”

For this research Crisp also is working with a lab at the University of Minnesota and one at the University of California at San Diego. He also worked with student Brian Gallagher ’09 in the summer of 2008 on a similar project.

Although the research is still in its early stages and is far from ready to transfer to humans, Crisp hopes that it can shed some light on the reasons for the successful use of dopamine on Parkinson’s patients. “It’s possible that we’ll raise some insights into ways to improve the technology. We might at least finally be able to explain something that we’ve observed for 50 years,” he says.

Recent News

May 20 - Book Review: Aging in the Key of Humor
May 19 - Press Release: The Michael J. Fox Foundation for Parkinson's Research Joins Multinational Critical Path for Parkinson's Consortium
May 19 - Congress reaches deal to overhaul chemical regulation
May 16 - Lifestyle: Why Parkinson's disease won't stop me rowing across the Pacific
May 16 - Many biomarkers for PD fail to inform on progression
May 10 - Parkinson's Cell Transplant Shows Good Reinnervation at 24 Years
May 7 - Growing art installation gathers stories of living with Parkinson's
May 5 - New technique can provide better cell transplants against Parkinson's disease
May 2 - What's Good For The Heart Is Good For The Brain
Apr 29 - Press Release: FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease
Apr 28 - Dopamine-making neurons can be chemically controlled in animal model of Parkinson's
Apr 25 - Lifestyle: Dating with Disease
Apr 25 - Scientific breakthrough in fight against Parkinson's and Alzheimer's
Apr 20 - Breakthrough Parkinson's disease blood test
Apr 15 - Living with Parkinson's
Apr 12 - Tissue biomarker for dementia with Lewy bodies and Parkinson’s disease
Apr 11 - Yoga for Every Body: Experts say yoga can ease pain and improve mobility for people with neurologic conditions
Apr 9 - Commonly prescribed Parkinson's drugs up risk of compulsive gambling, shopping, binge eating, hypersexuality
Apr 7 - Pfizer and IBM Launch Innovative Research Project to Transform Parkinson's Disease Care
Apr 7 - Parkinson's Drug Highly Effective for Resistant Depression